Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

EQS-News: Evotec and Pfizer collaborate to advance drug discovery in France: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec and Pfizer collaborate to advance drug discovery in France
EQS-News: Evotec and Pfizer collaborate to advance drug discovery in France
EQS-News: Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
EQS-News: Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030: https://mms.businesswire.com/media/20240702917901/en/2175827/5/Almirall_photovoltaic_installation_HQ_Barcelona.jpg
Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030


Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, launched its new sustainability strategy Act4Impact 2030 today. The updated strategy aims at transforming

EQS-News: Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret
EQS-News: Sartorius AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office – Supervisory Board expresses great regret
EQS-Adhoc: SARTORIUS AG: After more than 20 years as CEO,  Joachim Kreuzburg will not pursue another term in office : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-Adhoc: SARTORIUS AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office
EQS-Adhoc: SARTORIUS AG: After more than 20 years as CEO, Joachim Kreuzburg will not pursue another term in office
EQS-News: Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
EQS-News: Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
EQS-News: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
EQS-News: MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
EQS-Adhoc: Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
EQS-Adhoc: Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
Lockheed Martin Gives Thumbs Up to 1 Tiny Space Stock: https://g.foolcdn.com/editorial/images/780582/row-of-rockets-of-various-shapes-and-sizes.jpg
Lockheed Martin Gives Thumbs Up to 1 Tiny Space Stock

Valued at $110 billion and doing nearly $70 billion in annual business, Lockheed Martin (NYSE: LMT) is the world's biggest defense company. It's also a major player in space.

Lockheed Martin builds

EQS-News: Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
EQS-News: Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb
EQS-News: Evotec SE: Results of the Annual General Meeting 2024: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE: Results of the Annual General Meeting 2024
EQS-News: Evotec SE: Results of the Annual General Meeting 2024
EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
EQS-Adhoc: Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
EQS-News: Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases
EQS-News: Evotec, Inserm, Lille University Hospital and Inserm Transfert enter collaboration to identify novel therapeutic targets in obesity and metabolic diseases
EQS-News: Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease
EQS-News: Evotec and CHDI Foundation extend strategic drug discovery collaboration in Huntington’s disease
EQS-News: Gerresheimer expands capacities for Medical Systems in the USA: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-News: Gerresheimer expands capacities for Medical Systems in the USA
EQS-News: Gerresheimer expands capacities for Medical Systems in the USA
EQS-News: Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group – Strategic reset of Moulded Glass business: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-News: Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group – Strategic reset of Moulded Glass business
EQS-News: Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group – Strategic reset of Moulded Glass business
EQS-Adhoc: Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group / Moulded Glass business to be strategically reviewed: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-Adhoc: Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group / Moulded Glass business to be strategically reviewed
EQS-Adhoc: Gerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group / Moulded Glass business to be strategically reviewed
EQS-News: Evotec reports Q1 2024 results and provides corporate update: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec reports Q1 2024 results and provides corporate update
EQS-News: Evotec reports Q1 2024 results and provides corporate update
EQS-News: Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA
EQS-News: Sartorius to advance drug discovery and manufacturing with AI in collaboration with NVIDIA
EQS-News: Evotec SE to announce results for first quarter 2024 on 22 may 2024: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE to announce results for first quarter 2024 on 22 may 2024
EQS-News: Evotec SE to announce results for first quarter 2024 on 22 may 2024
EQS-News: Sartorius collaborates with Sanofi to commercialize end-to-end platform for downstream process intensification: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: Sartorius collaborates with Sanofi to commercialize end-to-end platform for downstream process intensification
EQS-News: Sartorius collaborates with Sanofi to commercialize end-to-end platform for downstream process intensification
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio: https://mms.businesswire.com/media/20240512974045/en/2128406/5/Almirall_fachada_R%26D_St_Feliu.jpg
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio


Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first quarter 2024. Almirall delivered strong sales growth in the first

Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?: https://g.foolcdn.com/editorial/images/776121/physician-talking-to-patient.jpg
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?

Many billionaire investors are going all in on artificial intelligence (AI). That's understandable. AI is quickly being integrated into businesses' day-to-day operations. The leaders in the field

EQS-News: RHÖN-KLINIKUM AG starts financial year 2024 with a good first quarter : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23735/Rhoen-klinikum.svg.png
EQS-News: RHÖN-KLINIKUM AG starts financial year 2024 with a good first quarter
EQS-News: RHÖN-KLINIKUM AG starts financial year 2024 with a good first quarter
Geisinger and Acadia Healthcare Hold Groundbreaking Ceremony for New Behavioral Health Hospital in Danville: https://mms.businesswire.com/media/20240506592018/en/2123321/5/Acadia_GB5775_photo.jpg
Geisinger and Acadia Healthcare Hold Groundbreaking Ceremony for New Behavioral Health Hospital in Danville


Geisinger and Acadia Healthcare Company held a ceremony today to celebrate the start of construction on its previously announced state-of-the-art, 96-bed behavioral health hospital in Danville